About Pricing FAQs Providers Trials Blog

Login Get started

Finding studies

Your health journey, clearly organized.

Questions? feedback@clareohealth.com

Product

How it works
Pricing
For Providers
Trials

Company

About
Blog
FAQ

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Clareo Health | Lymphoma Clinical Trials in New York | 215 Studies

Clinical Trials LymphomaNew York

Lymphoma Clinical Trials in New York

Find 215 clinical trials for lymphoma near New York, New York. Connect with research centers in your area.

All Lymphoma trials nationwide All trials in New York

Order

Status

RecruitingNot yet recruitingActive, not recruitingEnrolling by invitationCompletedTerminated

Phase

Early phase 1Phase 1Phase 1–2Phase 2Phase 2–3Phase 3Phase 4No phase

Who can join

Healthy volunteers too

Showing 121-140 of 215 trials

CompletedEpratuzumab and Rituximab in Treating Patients With Previously Untreated Follicular Non-Hodgkin LymphomaRATIONALE: Monoclonal antibodies, such as epratuzumab and rituximab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread.NCT00553501·San Diego, California and 42 others

Lymphoma Trials in Other Cities

Los Angeles Chicago Houston Phoenix Philadelphia San Antonio

Data from ClinicalTrials.govTerms

TerminatedA Safety Study of SGN-CD19B in Patients With B-cell Non-Hodgkin LymphomaThe study will examine the safety profile of SGN-CD19B administered as a single agent.NCT02702141·Birmingham, Alabama and 15 others

TerminatedA Study of the Effects of AB-205 in Patients With Lymphoma Undergoing Autologous Hematopoietic Cell TransplantationHigh-dose chemotherapy followed by blood stem cell transplantation is administered to lymphoma patients with an intention to cure.NCT05181540·Gilbert, Arizona and 27 others

CompletedVaccine Therapy and Sargramostim After Rituximab in Treating Patients With Refractory or Progressive Non-Hodgkin's LymphomaRATIONALE: Monoclonal antibodies such as rituximab can locate cancer cells and either kill them or deliver cancer-killing substances to them without harming normal cells.NCT00071955·Stanford, California and 10 others

CompletedStudy of hA20 (Humanized Anti-CD20) in Patients With CD20+ Non-Hodgkin's LymphomaThis is a Phase I trial to look at safety and how a patient's body will tolerate the treatment at different dosages.NCT00285428·New York, New York and 2 others

CompletedStudy of Pralatrexate With Vitamin B12 and Folic Acid in Patients With Relapsed or Refractory Peripheral T-cell LymphomaPrimary • Determine the efficacy of pralatrexate with concurrent vitamin B12 and folic acid supplementation when administered to patients with relapsed or refractory peripheral…NCT00364923·Duarte, California and 31 others

Active not recruitingA Study to Evaluate Adverse Events of Subcutaneous (SC) Epcoritamab Administered in the Outpatient Setting in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Classic Follicular LymphomaB-cell Lymphoma is an aggressive and rare cancer of a type of immune cells (a white blood cell responsible for fighting infections).NCT05451810·Mobile, Alabama and 71 others

CompletedDiagnostic Study of Patients With Aggressive Non-Hodgkin's LymphomaRATIONALE: Determination of genetic markers for aggressive non-Hodgkin's lymphoma may help identify patients with this disease and help predict the outcome of treatment.NCT00003863·Anniston, Alabama and 68 others

RecruitingTesting Addition of an Anti-cancer Drug, Vorasidenib to Temozolomide, After Radiation for Advanced Brain CancerThis phase III trial compares the effect of vorasidenib to placebo in combination with usual treatment, temozolomide, in treating patients with newly diagnosed grade 3 astrocytoma…NCT07215910·Bakersfield, California and 120 others

Active not recruitingUlixertinib in Treating Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial)This phase II Pediatric MATCH trial studies how well ulixertinib works in treating patients with solid tumors that have spread to other places in the body (advanced), non-Hodgkin…NCT03698994·Birmingham, Alabama and 106 others

TerminatedA Phase 1-2, Multicenter, Open-Label Study of AEG35156 in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia and Indolent B-Cell LymphomasAEG35156 has shown early evidence of activity in patients with advanced indolent B-cell lymphomas in Phase 1 trials and merits further evaluation in this disease.NCT00768339·Burbank, California and 6 others

CompletedA Study of Fibrocaps™ in Surgical BleedingThe purpose of this study is to confirm the superiority of Fibrocaps plus gelatin sponge, as compared to gelatin sponge alone, for achieving hemostasis.NCT01527357·Birmingham, Alabama and 47 others

CompletedRituximab and/or Lenalidomide in Treating Patients With Follicular Non-Hodgkin's Lymphoma That is Not Refractory to RituximabMonoclonal antibodies, such as rituximab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread.NCT00238238·La Jolla, California and 78 others

TerminatedA Long Term Study To Evaluate The Safety And Tolerability Of CP-690,550 For Patients With Moderate To Severe Chronic Plaque PsoriasisThe main objective of this study is to evaluate the long-term safety of CP-690,550 in patients being treated for moderate to severe chronic plaque psoriasis.NCT01163253·Birmingham, Alabama and 322 others

CompletedDose Escalation & Expansion Study of Oral VRx-3996 & Valganciclovir in Subjects With EBV+ Lymphoid MalignanciesA two part, Phase 1b/2 study to define a recommended Phase 2 dose of VRx-3996 in combination with valganciclovir (Phase 1b) designed to evaluate the efficacy of this combination…NCT03397706·Los Angeles, California and 27 others

TerminatedComparative Trial for Pixantrone in Combination With Rituximab in Indolent Non-Hodgkin's LymphomaThe purpose of this study is to determine whether combining pixantrone (BBR 2778, INN name pending) with the monoclonal antibody rituximab, leads to an increase in the period of…NCT00060671·Tucson, Arizona and 37 others

Active not recruitingErdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial)This phase II Pediatric MATCH trial studies how well erdafitinib works in treating patients with solid tumors, non-Hodgkin lymphoma, or histiocytic disorders with FGFR mutations…NCT03210714·Birmingham, Alabama and 115 others

Active not recruitingEXHIT ENTRE Implementation Trial of High Intensity Versus Low Intensity StrategyThis study is a multi-site, cluster randomized, two group implementation trial comparing a low- versus high-intensity implementation strategy for supporting hospital-based opioid…NCT04921787·Boston, Massachusetts and 3 others

CompletedBortezomib and Lenalidomide in Treating Patients With Relapsed or Refractory Mantle Cell LymphomaThis phase II trial studies how well bortezomib and lenalidomide work in treating patients with mantle cell lymphoma that has come back after a period of improvement (refractory)…NCT00553644·Anaheim, California and 81 others

CompletedEfficacy and Safety Study of StemEx®, to Treat Subjects With High Risk Hematologic Malignancies, Following Myeloablative TherapyThe purpose of this study is to determine the efficacy and safety of transplanting StemEx® in patients with certain hematological malignancies.NCT00469729·Los Angeles, California and 29 others

PreviousPage 7 of 11Next

Other Conditions in New York

Breast Cancer Lung Cancer Prostate Cancer Colorectal Cancer Melanoma Leukemia